United Therapeutics (UTHR) Competitors $312.23 +1.57 (+0.51%) Closing price 04:00 PM EasternExtended Trading$307.34 -4.89 (-1.57%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock UTHR vs. BIIB, INCY, NBIX, BMRN, EXEL, MDGL, HALO, EXAS, IONS, and RGENShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. United Therapeutics vs. Its Competitors Biogen Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Halozyme Therapeutics Exact Sciences Ionis Pharmaceuticals Repligen United Therapeutics (NASDAQ:UTHR) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Do insiders & institutionals believe in UTHR or BIIB? 94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 10.3% of United Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher valuation & earnings, UTHR or BIIB? Biogen has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$3.08B4.58$1.20B$25.6212.19Biogen$10.00B2.04$1.63B$10.4613.32 Do analysts rate UTHR or BIIB? United Therapeutics currently has a consensus target price of $382.00, indicating a potential upside of 22.35%. Biogen has a consensus target price of $185.74, indicating a potential upside of 33.33%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 0 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.69Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34 Does the media prefer UTHR or BIIB? In the previous week, Biogen had 18 more articles in the media than United Therapeutics. MarketBeat recorded 33 mentions for Biogen and 15 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.74 beat Biogen's score of 1.11 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 15 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biogen 24 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Is UTHR or BIIB more profitable? United Therapeutics has a net margin of 40.36% compared to Biogen's net margin of 15.31%. United Therapeutics' return on equity of 18.73% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.36% 18.73% 16.49% Biogen 15.31%13.85%8.32% Which has more volatility & risk, UTHR or BIIB? United Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. SummaryUnited Therapeutics beats Biogen on 10 of the 16 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.08B$2.81B$5.83B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio12.1922.6631.1625.99Price / Sales4.58760.87474.86122.97Price / Cash10.79173.2237.1558.38Price / Book1.965.879.116.38Net Income$1.20B$31.83M$3.26B$265.56M7 Day Performance-0.29%1.78%2.06%1.89%1 Month Performance4.81%4.33%5.08%1.23%1 Year Performance-9.99%11.50%31.26%21.10% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.9113 of 5 stars$312.23+0.5%$382.00+22.3%-11.6%$14.08B$3.08B12.191,305Positive NewsBIIBBiogen4.8527 of 5 stars$128.00-2.0%$185.63+45.0%-32.5%$18.77B$9.68B12.247,605Positive NewsINCYIncyte4.7354 of 5 stars$79.19+1.0%$81.20+2.5%+34.9%$15.46B$4.24B18.002,617Trending NewsAnalyst ForecastNBIXNeurocrine Biosciences4.867 of 5 stars$123.98-0.8%$160.90+29.8%-10.3%$12.30B$2.51B36.681,800Positive NewsBMRNBioMarin Pharmaceutical4.9979 of 5 stars$56.80-0.9%$93.17+64.0%-37.3%$10.91B$2.85B16.853,040EXELExelixis4.9113 of 5 stars$37.41-0.8%$44.44+18.8%+47.0%$10.07B$2.17B17.991,147Trending NewsAnalyst RevisionMDGLMadrigal Pharmaceuticals3.5649 of 5 stars$349.50+1.1%$430.43+23.2%+58.9%$7.76B$180.13M-27.2090News CoverageAnalyst ForecastInsider TradeAnalyst RevisionHALOHalozyme Therapeutics4.7103 of 5 stars$62.92+0.0%$66.56+5.8%+15.2%$7.75B$1.02B14.40390News CoveragePositive NewsEXASExact Sciences4.9099 of 5 stars$40.91-0.2%$68.14+66.6%-21.8%$7.75B$2.76B-7.537,000IONSIonis Pharmaceuticals4.6315 of 5 stars$40.84-1.9%$59.38+45.4%-10.3%$6.51B$944.05M-22.201,069Trending NewsAnalyst ForecastInsider TradeRGENRepligen4.8627 of 5 stars$111.88+0.4%$169.45+51.5%-21.8%$6.29B$673.96M-447.501,778News CoveragePositive News Related Companies and Tools Related Companies BIIB Alternatives INCY Alternatives NBIX Alternatives BMRN Alternatives EXEL Alternatives MDGL Alternatives HALO Alternatives EXAS Alternatives IONS Alternatives RGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access